-
PR 8.33
Clinical Outcomes of Radioactive Iodine Therapy in Patients with Negative Pre-therapy I-131 Scans After Redifferentiation Therapy for RAI-Refractory Thyroid Cancer
-
60 8.03
Prognostic Impact of Pre-Transplant Measurable Residual Disease in Acute Myeloid Leukemia: A Bayesian Meta-Analysis of Contemporary Allogeneic Hematopoietic Cell Transplantation Cohorts
-
51 7.73
Distinct IL-1/VEGF-Dominant Phenotype in IL-6-Refractory Multicentric Castleman Disease: A Pooled Matched Analysis of Anakinra versus IL-6 Blockade
-
157 7.5
CAR-T Therapies Associated with Higher CRS-Linked Cardiotoxicity Signal than BiTE Agents in Multiple Myeloma: Analysis of Adverse Event Report
-
54 7.17
Therapeutic Architecture Rather Than Population Differences Drives Front-Line Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts
-
59 6.5
POST-CART: Primary Care Oversight and Survivorship After CAR-T — A Pilot Cross-Sectional Survey
-
52 6.4
Steroid Non-Response Predicts IL-6 Blockade Failure and Defines a Non-IL-6-Dominant Inflammatory Subset in TAFRO Syndrome: A Pooled Patient-Level Analysis
-
55 6.4
Differential Toxicity Patterns with Bispecific Antibody Monotherapy and Daratumumab-Based Combinations in Multiple Myeloma - A Pooled Analysis
-
64 4.9
Clinical Predictors of Remission in TAFRO Syndrome: A Pooled Meta Analysis of 70 Published Cases
